Delfi Diagnostics

DELFI Diagnostics is a precision oncology company, founded in 2019 and built on research from the Johns Hopkins Kimmel Cancer Center, that combines machine learning with genome-wide analysis of cell-free DNA fragmentation patterns (an approach it calls DNA fragmentomics, or "fragmentomes") to develop accessible, blood-based cancer screening and treatment-monitoring tests. Its first commercial product, FirstLook Lung, is a laboratory-developed liquid biopsy screening test for lung cancer that runs from a simple blood draw and reports a high negative predictive value; the company also offers DELFI-TF for treatment monitoring and partners with health systems and pharmaceutical researchers. DELFI operates a CLIA laboratory and is headquartered in Palo Alto, California. This profile tracks the company in the API Evangelist network; DELFI publishes no public developer API surface.

Delfi Diagnostics is profiled on the APIs.io network. Tagged areas include Company, Diagnostics, Precision Oncology, Liquid Biopsy, and Cancer Screening.

Delfi Diagnostics’ developer surface includes engineering blog, support, YouTube channel, and 7 more developer resources.

🌐 Visit website 📡 Source on GitHub

15.0/100 emerging ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyDiagnosticsPrecision OncologyLiquid BiopsyCancer ScreeningGenomicsMachine LearningHealthcare

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 15.0/100 · emerging

Contract Quality 0.0 / 25

Developer Ergonomics 1.3 / 20

Commercial Clarity 4.2 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/delfi-diagnostics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Learn 1

Tutorials, courses, talks, and written guidance

YouTube

YouTube

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

TermsOfService

TermsOfService

Company 5

The organization behind the API

Website

About

Blog

Newsroom

LinkedIn

Source (apis.yml)

aid: delfi-diagnostics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/delfi-diagnostics.png
name: Delfi Diagnostics
description: DELFI Diagnostics is a precision oncology company, founded in 2019 and built on research from the Johns Hopkins
  Kimmel Cancer Center, that combines machine learning with genome-wide analysis of cell-free DNA fragmentation patterns (an
  approach it calls DNA fragmentomics, or "fragmentomes") to develop accessible, blood-based cancer screening and treatment-monitoring
  tests. Its first commercial product, FirstLook Lung, is a laboratory-developed liquid biopsy screening test for lung cancer
  that runs from a simple blood draw and reports a high negative predictive value; the company also offers DELFI-TF for treatment
  monitoring and partners with health systems and pharmaceutical researchers. DELFI operates a CLIA laboratory and is headquartered
  in Palo Alto, California. This profile tracks the company in the API Evangelist network; DELFI publishes no public developer
  API surface.
url: https://raw.githubusercontent.com/api-evangelist/delfi-diagnostics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- menlo-ventures
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Diagnostics
- Precision Oncology
- Liquid Biopsy
- Cancer Screening
- Genomics
- Machine Learning
- Healthcare
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/delfi-diagnostics-domain-security.yml
- type: Website
  url: https://delfidiagnostics.com
- type: About
  url: https://delfidiagnostics.com/about-us/
- type: Blog
  url: https://delfidiagnostics.com/about-us/blog/
- type: Newsroom
  url: https://delfidiagnostics.com/about-us/newsroom/
- type: Support
  url: https://delfidiagnostics.com/contact/
- type: PrivacyPolicy
  url: https://delfidiagnostics.com/privacy-policy/
- type: TermsOfService
  url: https://delfidiagnostics.com/terms/
- type: LinkedIn
  url: https://www.linkedin.com/company/delfi-diagnostics/
- type: YouTube
  url: https://www.youtube.com/channel/UCv7e-20ef3HAJ4urkQ3porw
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence